Pricing Log in Create free account

Clearside Biomedical, Inc. (CLSDQ) vs Kairos Pharma, Ltd. (KAPA)

Clearside Biomedical, Inc. and Kairos Pharma, Ltd. are both Biotechnology companies. Clearside Biomedical, Inc. and Kairos Pharma, Ltd. are of similar size ($2.3M and $2.2M). Kairos Pharma, Ltd. has the higher net margin (0.00% vs −780.9%) and the lower return on invested capital (−322.9% vs 0.00%). Across the 12 metrics below, Kairos Pharma, Ltd. leads on 8 and Clearside Biomedical, Inc. on 4.

Valuation

Metric CLSDQ KAPA Biotechnology median
P/E n/m n/m 8.50
P/S 0.39 n/m 9.71
P/B n/m 0.44 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.18 0.14 0.64
EV/Sales (1.24) n/m 9.21
Earnings yield (2,075.24%) (326.58%) (33.15%)
Free cash flow yield (1,661.90%) (216.16%) (25.50%)

Profitability

Metric CLSDQ KAPA Biotechnology median
Gross margin 92.55% — 65.16%
Operating margin (689.76%) 0.00% 0.00%
Net margin (780.93%) 0.00% 0.00%
Free cash flow margin (653.23%) 0.00% 0.00%
Return on equity 58.59% (113.96%) (56.36%)
Return on assets (127.43%) (104.32%) (48.04%)
Return on invested capital 0.00% (322.91%) 0.00%

Growth

Metric CLSDQ KAPA Biotechnology median
Revenue growth (TTM) (56.78%) — 6.02%
EPS growth (last fiscal year) 11.32% (30.44%) 30.26%
Revenue growth, 5-year CAGR (5.20%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CLSDQ KAPA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.98 11.98 4.72
Net debt to EBITDA 0.69 1.65 0.96

Dividend

Metric CLSDQ KAPA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLSDQ KAPA Biotechnology median
Market cap 2.15m 2.27m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack